Wall Street Zen Upgrades Delcath Systems (NASDAQ:DCTH) to "Buy"

Delcath Systems (NASDAQ:DCTH - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

DCTH has been the topic of a number of other reports. Stephens reaffirmed an "overweight" rating and issued a $25.00 price target on shares of Delcath Systems in a research note on Monday, June 23rd. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Delcath Systems in a research report on Saturday, September 27th. Finally, HC Wainwright raised their price target on shares of Delcath Systems from $29.00 to $31.00 and gave the company a "buy" rating in a research report on Thursday, August 7th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, Delcath Systems has a consensus rating of "Moderate Buy" and a consensus target price of $24.50.

Delcath Systems Stock Up 4.2%

Delcath Systems stock opened at $11.10 on Friday. The business has a fifty day moving average of $10.92 and a two-hundred day moving average of $12.56. The firm has a market cap of $388.28 million, a P/E ratio of 222.00 and a beta of 0.84. Delcath Systems has a twelve month low of $8.08 and a twelve month high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.05. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%.The firm had revenue of $24.16 million for the quarter, compared to the consensus estimate of $22.84 million. Equities analysts expect that Delcath Systems will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Delcath Systems

Large investors have recently made changes to their positions in the business. Palisades Investment Partners LLC boosted its stake in shares of Delcath Systems by 58.0% in the second quarter. Palisades Investment Partners LLC now owns 270,310 shares of the company's stock valued at $3,676,000 after purchasing an additional 99,226 shares during the period. Vanguard Group Inc. lifted its position in Delcath Systems by 13.8% in the 1st quarter. Vanguard Group Inc. now owns 1,394,028 shares of the company's stock valued at $17,746,000 after purchasing an additional 169,260 shares during the last quarter. Principal Financial Group Inc. boosted its position in Delcath Systems by 2.1% during the 1st quarter. Principal Financial Group Inc. now owns 117,620 shares of the company's stock worth $1,497,000 after acquiring an additional 2,437 shares during the period. Bank of America Corp DE raised its position in shares of Delcath Systems by 1,816.5% during the 4th quarter. Bank of America Corp DE now owns 25,700 shares of the company's stock worth $309,000 after buying an additional 24,359 shares in the last quarter. Finally, Invesco Ltd. bought a new stake in shares of Delcath Systems during the 1st quarter worth about $5,084,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.